Note: This document contains side effect information about reslizumab. Some dosage forms listed on this page may not apply to the brand name Cinqair.
Applies to reslizumab: intravenous solution.
Warning
Intravenous route (Solution)
Anaphylaxis has been observed with reslizumab infusion in 0.3% of patients in placebo-controlled clinical studies. Anaphylaxis was reported as early as the second dose of reslizumab. Anaphylaxis can be life-threatening. Patients should be observed for an appropriate period of time after reslizumab administration by a healthcare professional prepared to manage anaphylaxis. Discontinue reslizumab immediately if the patient experiences signs or symptoms of anaphylaxis.
Serious side effects of Cinqair
Along with its needed effects, reslizumab (the active ingredient contained in Cinqair) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking reslizumab:
Rare
- Cough
- difficulty with swallowing
- dizziness
- dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
- fast heartbeat
- hives, itching, or skin rash
- puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
- redness of the skin
- tightness in the chest
- unusual tiredness or weakness
Other side effects of Cinqair
Some side effects of reslizumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Less common
- Throat pain
Incidence not known
- Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site
For Healthcare Professionals
Applies to reslizumab: intravenous solution.
Gastrointestinal
Common (1% to 10%): Oropharyngeal pain[Ref]
Hematologic
Very common (10% or more): Elevated baseline creatine phosphokinase (CPK) (14%)[Ref]
Hypersensitivity
Uncommon (0.1% to 1%): Anaphylaxis[Ref]
Immunologic
Common (1% to 10%): Treatment emergent anti-reslizumab (the active ingredient contained in Cinqair) antibody response (low titer and often transient)[Ref]
Musculoskeletal
Very common (10% or more): Elevated baseline creatine phosphokinase (CPK) (14%)
Common (1% to 10%): Myalgia, chest pain, neck pain, muscle spasms, extremity pain, muscle fatigue, musculoskeletal pain[Ref]
Oncologic
Frequency not reported: Malignancy[Ref]
